Strategic approach to produce low-cost, efficient, and stable competitive internal controls for detection of RNA viruses by use of reverse transcription-PCR.
Molecular diagnostics based on reverse transcription (RT)-PCR are routinely complicated by the lack of stable internal controls, leading to falsely negative results. We describe a strategy to produce a stable competitive internal control (CIC) based on a Qbeta phage derivative (recombinant Qbeta [rQbeta]) bearing primers KY78 and KY80, which are widely used in the detection of hepatitis C virus (HCV). rQbeta was RNase resistant and stable at 4 degrees C for 452 days in SM medium (0.1 M NaCl, 8 mM MgSO(4).7H(2)O, 50 mM Tris HCl [pH 7.5], 2% gelatin) and for 125 days after lyophilization and reconstitution. rQbeta performance as a CIC was evaluated. rQbeta was added to HCV-positive samples, followed by RNA extraction and a CIC-HCV RT-PCR assay. This method combines RT-PCR, liquid hybridization with nonradioactive probes, and enzyme immunoanalysis. No influence of the CIC on qualitative HCV detection was observed independently of viral load, and results had high concordance with those of commercial kits. In conclusion, we describe a versatile, low-cost alternative strategy to armored RNA technology that can be adapted for detection or real-time applications of any RNA target. Moreover, the CIC reported here is an essential reagent for HCV screening in blood banks in resource-limited settings.
Villanova
Gabriela V
GV
Area Virología, Facultad de Ciencias Bioquímicas y Farmacéuticas, Instituto de Biología Molecular y Celular de Rosario, Universidad Nacional de Rosario, Suipacha 531, 2000, Rosario, Argentina.
Gardiol
Daniela
D
Taborda
Miguel A
MA
Reggiardo
Virginia
V
Tanno
Hugo
H
Rivadeneira
Emilia D
ED
Perez
Germán R
GR
Giri
Adriana A
AA
D001483:Base Sequence; D003090:Coliphages / Q000235:genetics*; D016174:Hepacivirus / Q000302:isolation & purification*; D006801:Humans; D008969:Molecular Sequence Data; D012367:RNA, Viral / Q000097:blood; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D012680:Sensitivity and Specificity
D012367:RNA, Viral
J Clin Microbiol. 2001 Dec;39(12):4302-8
11724836
Swiss Med Wkly. 2001 Jun 2;131(21-22):291-8
11584690
Clin Microbiol Infect. 2004 Jan;10(1):5-11
14706081
J Virol Methods. 2004 Mar 1;116(1):45-54
14715306
J Clin Virol. 2004 Feb;29(2):84-91
14747025
J Clin Microbiol. 2004 Feb;42(2):841-3
14766868
NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46
14768714
J Clin Microbiol. 2004 Mar;42(3):1003-11
15004045
J Clin Microbiol. 2004 Jul;42(7):3059-64
15243060
J Clin Microbiol. 1993 Apr;31(4):882-6
8385151
J Clin Microbiol. 1994 Feb;32(2):292-300
8150937
J Mol Biol. 1994 Nov 11;243(5):811-5
7966301
FEBS Lett. 1995 Feb 6;359(1):89-92
7851538
J Clin Microbiol. 1995 Mar;33(3):654-7
7751372
J Clin Microbiol. 1997 Feb;35(2):511-4
9003630
J Mol Biol. 1998 Jan 30;275(4):589-600
9466933
FEBS Lett. 1998 Jul 10;431(1):7-11
9684855
RNA. 1998 Aug;4(8):948-57
9701286
J Clin Microbiol. 1998 Dec;36(12):3590-4
9817878
Vox Sang. 1999;76(3):149-58
10341329
Vox Sang. 1999;76(3):170-4
10341333
J Clin Microbiol. 1999 Jul;37(7):2361-5
10364617
Medicina (B Aires). 2004;64(5):419-28
15560543
J Clin Microbiol. 2005 Sep;43(9):4551-7
16145106
Clin Chem Lab Med. 2005;43(8):827-33
16201892
J Clin Microbiol. 2006 Jan;44(1):67-70
16390950
J Virol Methods. 2006 Mar;132(1-2):135-45
16274751
Int J Mol Med. 2006 Nov;18(5):995-1003
17016633
Clin Chem. 1999 Dec;45(12):2079-85
10585339
CMAJ. 2000 Mar 21;162(6):827-33
10750473
J Viral Hepat. 1999 Jan;6(1):35-47
10847128
J Clin Microbiol. 2000 Dec;38(12):4560-8
11101596
J Clin Microbiol. 2003 May;41(5):2055-61
12734248